LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Factores asociados para prediabetes en pacientes con virus de inmunodeficiencia humana.

    Jiménez-Villalba, Yeimmy Zuyenn / Madrigal-Santillán, Duardo Osiris / González-Virla, Baldomero José Gregorio / Iniestra-Frías, Luis Angel / Durán-Gómez, Verónica

    Revista medica del Instituto Mexicano del Seguro Social

    2023  Volume 61, Issue Suppl 3, Page(s) S380–S386

    Abstract: Introduction: HIV disease was transformed from a fatal condition to one with metabolic complications. In Mexico City, the associated factors for prediabetes in this population are unknown; investigating it is relevant to improve their quality of life.!## ...

    Title translation Associated factors for prediabetes in patients with human immunodeficiency virus.
    Abstract Introduction: HIV disease was transformed from a fatal condition to one with metabolic complications. In Mexico City, the associated factors for prediabetes in this population are unknown; investigating it is relevant to improve their quality of life.
    Objective: To determine the risk association factors for prediabetes in people living with HIV.
    Material and methods: Cross-analytical, retrospective study. Records of patients living with HIV were reviewed, exposure factors and fasting glucose concentration were recorded. Patients from 18 to 65 years of age were included, on co-formulated antiretroviral treatment, without adjustment of antiretroviral treatment in the last two years, with a BMI of 18.5-40 kg/m2.
    Results: 148 patients were included, 68 presented prediabetes. The factors with risk association that were identified are: age over 60 years (OR 9.48, 95% CI 1.68-40.13), treatment with Efavirenz/Tenofovir/Emtricitabine (OR 9.28, 95% CI 2.55-33.74) and treatment time antiretroviral older than 12 months (OR 2.53, 95% CI .912-7.041).
    Conclusion: The prevalence of prediabetes in people living with HIV is 46%. The main associated factor was the consumption of Atripla. This study has clinical relevance since it will allow the implementation of prevention, diagnosis and treatment strategies for prediabetes in order to reduce associated morbidity and mortality.
    MeSH term(s) Humans ; Child, Preschool ; Middle Aged ; Prediabetic State/diagnosis ; Prediabetic State/epidemiology ; Prediabetic State/etiology ; HIV ; Quality of Life ; Retrospective Studies ; HIV Infections/complications ; HIV Infections/drug therapy ; HIV Infections/epidemiology
    Language Spanish
    Publishing date 2023-10-02
    Publishing country Mexico
    Document type English Abstract ; Journal Article ; Observational Study
    ZDB-ID 732133-8
    ISSN 2448-5667 ; 0443-5117 ; 0484-7849
    ISSN (online) 2448-5667
    ISSN 0443-5117 ; 0484-7849
    DOI 10.5281/zenodo.8319825
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 2225: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Pentoxifylline decreases serum LDH levels and increases lymphocyte count in COVID-19 patients: Results from an external pilot study.

    Maldonado, Valente / Hernandez-Ramírez, Claudia / Oliva-Pérez, Eniel Alonso / Sánchez-Martínez, César Omar / Pimentel-González, Jorge Fabián / Molina-Sánchez, José Raúl / Jiménez-Villalba, Yeimmy Zuyenn / Chávez-Alderete, Jaime / Loza-Mejía, Marco A

    International immunopharmacology

    2020  Volume 90, Page(s) 107209

    Abstract: We have previously hypothesized that pentoxifylline could be beneficial for the treatment of COVID-19 given its potential to restore the immune response equilibrium, reduce the impact of the disease on the endothelium and alveolar epithelial cells, and ... ...

    Abstract We have previously hypothesized that pentoxifylline could be beneficial for the treatment of COVID-19 given its potential to restore the immune response equilibrium, reduce the impact of the disease on the endothelium and alveolar epithelial cells, and improve the circulatory function.Serum lactate dehydrogenase (LDH) and lymphocyte count are accessible biomarkers that correlate with the severity of COVID-19, the need for hospitalization, and mortality, reflecting the host immune response's contribution to the seriousness of SARS-CoV-2 infection. We carried out this external pilot study on 38 patients with moderate and severe COVID-19 to test the effect pentoxifylline on parameters such as LDH, lymphocyte count, days of hospitalization, mortality, and proportion of patients requiring intubation. Twenty-six patients were randomized to receive 400 mg of pentoxifylline t.i.d. plus standard therapy (pentoxifylline group), while the rest received the standard treatment (control group). Linear regression models were built for statistically significant parameters. Pentoxifylline treatment was associated with a 64.25% increase (CI95% 11.83, 116.68) in lymphocyte count and a 29.61% decrease (CI95% 15.11, 44.10) in serum LDH. Although a trend towards reduced days of hospitalization, mortality, and proportion of patients requiring intubation was observed, no statistically significant difference was found for these parameters. Our findings open the possibility of pentoxifylline being repositioned as a drug for COVID-19 treatment with the advantages of a proven safety profile, availability, and no risk of immunosuppression; however, this evidence needs to be confirmed in a pragmatic randomized controlled trial.
    MeSH term(s) Aged ; Biomarkers/blood ; COVID-19/blood ; COVID-19/drug therapy ; COVID-19/immunology ; Drug Repositioning ; Female ; Humans ; L-Lactate Dehydrogenase/blood ; Lymphocyte Count ; Male ; Middle Aged ; Pentoxifylline/pharmacology ; Pentoxifylline/therapeutic use ; Pilot Projects ; SARS-CoV-2
    Chemical Substances Biomarkers ; L-Lactate Dehydrogenase (EC 1.1.1.27) ; Pentoxifylline (SD6QCT3TSU)
    Language English
    Publishing date 2020-11-26
    Publishing country Netherlands
    Document type Journal Article ; Randomized Controlled Trial
    ZDB-ID 2043785-7
    ISSN 1878-1705 ; 1567-5769
    ISSN (online) 1878-1705
    ISSN 1567-5769
    DOI 10.1016/j.intimp.2020.107209
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5408: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top